LivaNova Q3 Earnings Call Highlights
LivaNova (LIVN) updated its 2026 revenue growth outlook to 9-10% from 8-9%, with Cardiopulmonary revenue growth raised to 10.5-11.5%. Epilepsy revenue grew 11% YoY, and the company raised its 2026 epilepsy revenue growth forecast to 8-9%. LivaNova expects a double-digit increase in oxygenator output in 2027 and plans product launches in 2027-2028. The company also highlighted positive clinical study results and strategic hires for its OSA technology.
How this was made
The 30-second read
Why it matters
The most tradable elements are the raised 2026 revenue growth outlook and adjusted EPS range, plus operational milestones (oxygenator line operational) and reimbursement-supporting developments (AMA Category 1 CPT codes expected to take effect Jan. 1, 2028).
Market read
Investors can update 2026 expectations immediately from the raised guidance and assess how 2027-2028 product ramps and reimbursement changes may affect longer-term growth.
What to watch
Tariff exposure is quantified as less than $5M net impact, but investors may still scrutinize supply-chain dependencies (critical components) and the pace of next-generation product validation and PMA supplement timing.
Background
The piece summarizes LivaNova’s Q3 earnings call, covering manufacturing capacity for a dedicated oxygenator line, next-generation oxygenator and OSA timelines, and updates to cardiopulmonary and epilepsy growth outlooks.
Ticker impact
LivaNova raised 2026 revenue growth and EPS guidance, and detailed 2027-2028 oxygenator and OSA product timelines on its Q3 earnings call.
Likely upward bias as investors reprice 2026 growth and margin outlook, tempered by execution risk into the 2027-2028 launches.
The article contains explicit raised 2026 revenue growth and adjusted EPS guidance plus operational updates (oxygenator line operational, OSA CPT code support), which are direct inputs to valuation and expectations.
Market effects
Reinforces demand and reimbursement momentum in neuromodulation and cardiopulmonary device markets, potentially supporting peer sentiment around device adoption and coding.
Limited direct regional read-through; guidance is company-specific with global revenue mix.
Moderate global relevance via reimbursement and device manufacturing capacity expansion themes, but no cross-border policy shock described.
Counterpoint
Raised guidance may already be partially anticipated; the market may focus more on whether OSA and oxygenator ramps translate into sustained margins beyond 2026.
Key entities
- companyLivaNova PLC
NASDAQ-listed medical technology company providing neuromodulation and cardiopulmonary devices and therapies.
- companyThermo Fisher
Referenced as part of a previously announced agreement supporting supply of critical components.
- organizationAmerican Medical Association (AMA)
Editorial panel established Category 1 CPT codes expected to take effect Jan. 1, 2028 for OSA-related services.
